A Phase 2, Randomized, Triple-Blinded, Active-Controlled Study to Assess the Safety and Immunogenicity of an Investigational Herpes Zoster (HZ) Vaccine, JCXH-105, in Healthy Subjects ≥ 50 Years of Age
Latest Information Update: 09 Dec 2024
Price :
$35 *
At a glance
- Drugs GSK 137173A (Primary) ; JCXH-105 (Primary)
- Indications Herpes zoster
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Immorna
- 04 Dec 2024 Status changed from not yet recruiting to recruiting.
- 19 Sep 2024 Planned initiation date changed from 1 Sep 2024 to 20 Sep 2024.
- 04 Sep 2024 New trial record